The Effect of MK0633 in Patients With Chronic Asthma (0633-007)

NCT00404313 ↗

Phase 2 Terminated 688 enrolled Merck Sharp & Dohme LLC

RandomizedParallel-groupDouble-blindTreatment

Summary

A clinical study to evaluate the efficacy and safety of MK0633 in adult patients with chronic asthma.

Timeline

Start: 2008-01
Primary completion: 2009-06
Completion: 2009-06

Outcome

Met primary endpoint

paper MK-0633 100 mg was significantly more effective than placebo for the change from baseline in FEV(1) (0.20 L vs. 0.13 L; p = 0.004). PMID 21945511 ↗

Publications

Results Wasfi YS, Villaran C, de Tilleghem Cle B, Smugar SS, Hanley WD, Reiss TF, Knorr BA. The efficacy and tolerability of MK-0633, a 5-lipoxygenase inhibitor, in chronic asthma. Respir Med. 2012 Jan;106(1):34-46. doi: 10.1016/j.rmed.2011.08.019. Epub 2011 Sep 25.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SETILEUTON	Small molecule	10 mg	—
Subject	SETILEUTON	Small molecule	50 mg	—
Subject	SETILEUTON	Small molecule	100 mg	—